Evidence map›Paper›PMID 40151322›Full record

Trial reportJournal of diabetes research2025

Effect of Empagliflozin on Serum Ferritin and Its Relationship With Inflammatory Markers in Prediabetic and Diabetic Patients.

Mojgan Sanjari, Narges Sadeghi, Azade Ramezannezhad, Zohre Safi, Ahmad Naghibzadeh-Tahami, Ladan Amirkhosravi

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mojgan SanjariEndocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Narges SadeghiEndocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Azade RamezannezhadPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0009-0003-5259-4090
Zohre SafiPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Ahmad Naghibzadeh-TahamiModeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Ladan AmirkhosraviEndocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran.ORCID https://orcid.org/0000-0001-9174-1426

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Benzhydryl CompoundsDiabetes Mellitus, Type 2FerritinsGlucosidesInflammationPrediabetic StateSodium-Glucose Transporter 2 InhibitorsAdolescentAdultAgedBiomarkersBlood GlucoseC-Reactive ProteinFemaleGlycated HemoglobinHumansBenzhydryl CompoundsBiomarkersBlood GlucoseC-Reactive ProteinempagliflozinFerritinsGlucosidesGlycated HemoglobinInterleukin-6Sodium-Glucose Transporter 2 InhibitorsUric AcidCRPferritininterleukin-6iron metabolismsodium–glucose cotransporter-2 inhibitorsuric acid

Identifiers

PMID40151322
PMCPMC11949612

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.